just think while anyone in the USA will be stuck waiting on fda approval for the drug development (years away), we are already "approved" here via the authorised provider scheme. by the time they get around to approval it will be day one for them of actually delivering the clinical model. (and likely to be very rigid).
emd on the other hand will likely have a good ~2-3 years under its belt along with data of actually delivering the clinical service, we are not rigid and so able to be agile and adapt our clinical model to the feedback and learnings that we receive from our real world data. even when others catch up they will unlikely to be able to do this. or at least it would need to rego though a complex approval process again.
the fact we can adapt and change quickly is going to compound our learnings much faster that our competitors.
even our local competition is starting from zero customers and what looks to be a single psychiatrist - think of the holistic and wrap around services and experience that the pax centre has to deliver the support services that will be actually needed. these mdma/trip sessions are not light hearted its multiple psychiatrists involved multiple long sessions (half day to day) lots of intervention.
Add to My Watchlist
What is My Watchlist?
